The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 9: 1267 - 1272

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.09.001

Symposiums

The role of biomarkers in the diagnosis and prediction of disease progression of IgA nephropathy

  • Lu ZHAO ,
  • Huiwen ZHI ,
  • Yafeng LI
Expand
  • Department of Nephrology，Shanxi Provincial People's Hospital，Shanxi Medical University，the Fifth Clinical Medical College of Shanxi Medical University，Taiyuan 030012，Shanxi，China

Received date: 2024-12-07

  Online published: 2025-05-20

Fold

Abstract

IgA nephropathy （IgAN） is one of the most prevalent forms of primary glomerulonephritis globally and a leading cause of end?stage renal disease （ESRD）. The exact pathogenesis and progression mechanisms of IgAN remain unclear. Its clinical manifestations are diverse， with varying degrees of kidney involvement reflected in both clinical presentations and pathological changes. Consequently， responses to treatment and prognoses differ significantly among patients. Currently， renal needle biopsy serves as the gold standard for diagnosing IgAN； however， this invasive procedure is often not well?accepted by patients， limiting its widespread clinical application and complicating disease diagnosis. Therefore， non?invasive biomarkers are crucial for assisting in the diagnosis of IgAN and evaluating the risk of disease progression. Below， we will focus on various serum and urinary biomarkers associated with IgAN at both protein and nucleic acid levels.

Key words： IgA nephropathy; biomarkers; protein; nucleic acid; diagnosis; progression

Cite this article

Lu ZHAO , Huiwen ZHI , Yafeng LI . The role of biomarkers in the diagnosis and prediction of disease progression of IgA nephropathy[J]. The Journal of Practical Medicine, 2025 , 41(9) : 1267 -1272 . DOI: 10.3969/j.issn.1006-5725.2025.09.001

References

1 STAMELLOU E， SEIKRIT C， TANG S C W， et al. IgA nephropathy［J］. Nat Rev Dis Primers， 2023， 9（1）： 67. doi:10.1038/s41572-023-00476-9
2 CHEUNG C K， ALEXANDER S， REICH H N， et al. The pathogenesis of IgA nephropathy and implications for treatment［J］. Nat Rev Nephrol， 2025， 21（1）： 9-23. doi:10.1038/s41581-024-00885-3
3 涂宇豪，郭志良，萨如拉，等. 703例次移植肾穿刺活组织检查的病理诊断分析［J］. 器官移植， 2024，15（5）：799-804.
4 SCHIMPF J， KRONBICHLER A， WINDPESSL M， et al. Diagnosis and Treatment of IgA Nephropathy［J］. Wien Klin Wochenschr， 2023， 135（）： 621-627. doi:10.1007/s00508-023-02257-6
5 GENTILE M， SANCHEZ-RUSSO L， RIELLA L V， et al. Immune abnormalities in IgA nephropathy［J］. Clin Kidney J， 2023， 16（7）： 1059-1070. doi:10.1093/ckj/sfad025
6 GHARAVI A G， MOLDOVEANU Z， WYATT R J， et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy［J］. J Am Soc Nephrol， 2008， 19（5）： 1008-1014. doi:10.1681/asn.2007091052
7 LECHNER S M， PAPISTA C， CHEMOUNY J M， et al. Role of IgA receptors in the pathogenesis of IgA nephropathy［J］. J Nephrol， 2016， 29（1）：5-11. doi:10.1007/s40620-015-0246-5
8 SMITH D A， REDMAN J E， FRASER D J， et al. Identification and detection of microRNA kidney disease biomarkers in liquid biopsies［J］. Curr Opin Nephrol Hypertens， 2023， 32（6）： 515-521. doi:10.1097/mnh.0000000000000927
9 SERINO G， SALLUSTIO F， COX S N， et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy［J］. J Am Soc Nephrol， 2012， 23（5）： 814-824. doi:10.1681/asn.2011060567
10 SERINO G， SALLUSTIO F， CURCI C， et al. Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy［J］. Nephrol Dial Transplant， 2015， 30（7）： 1132-1139. doi:10.1093/ndt/gfv032
11 SERINO G， PESCE F， SALLUSTIO F， et al. In a retrospective international study， circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy［J］. Kidney Int， 2016， 89（3）： 683-692. doi:10.1038/ki.2015.333
12 SUZUKI H， ALLEGRI L， SUZUKI Y， et al. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy？［J］. Dis Markers， 2016， 2016： 7806438. doi:10.1155/2016/7806438
13 SZETO C C， WANG G， NG J K C， et al. Urinary miRNA profile for the diagnosis of IgA nephropathy［J］. BMC Nephrol， 2019， 20（1）： 77. doi:10.1186/s12882-019-1267-4
14 LI S， HAO H， LI R， et al. Urinary Exosomal MicroRNAs as New Noninvasive Biomarkers of IgA Nephropathy［J］. Tohoku J Exp Med， 2022， 256（3）： 215-223. doi:10.1620/tjem.256.215
15 ZHANG Q， ZHAO Y， LUO Y， et al. Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis， reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy［J］. Renal Fail， 2024， 46（1）： 2319326. doi:10.1080/0886022x.2024.2319326
16 ZHAO S， SUN Y， MAO Q， et al. Exosomal miR-4639 and miR-210 in Plasma and Urine as Biomarkers in IgA Nephropathy［J］. Nephron， 2022， 146（6）： 539-552. doi:10.1159/000523924
17 MIN Q H， CHEN X M， ZOU Y Q， et al. Differential expression of urinary exosomal microRNAs in IgA nephropathy［J］. J Clin Lab Anal， 2018， 32（2）： e22226. doi:10.1002/jcla.22226
18 MARTINS B， FERNANDES R. Disturbed Matrix Metalloproteinases Activity in Age-Related Macular Degeneration［J］. Adv Exp Med Biol， 2023， 1415： 21-26. doi:10.1007/978-3-031-27681-1_4
19 ZHANG J， REN P， WANG Y， et al. Serum Matrix Metalloproteinase-7 Level is Associated with Fibrosis and Renal Survival in Patients with IgA Nephropathy［J］. Kidney Blood Press Res， 2017， 42（3）： 541-552. doi:10.1159/000477132
20 GENEST D S， BONNEFOY A， KHALILI M， et al. Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis［J］. Kidney Int Rep， 2022， 7（5）： 1027-1036. doi:10.1016/j.ekir.2022.02.002
21 MAILLARD N， WYATT R J， JULIAN B A， et al. Current Understanding of the Role of Complement in IgA Nephropathy［J］. J Am Soc Nephrol， 2015， 26（7）： 1503-1512. doi:10.1681/asn.2014101000
22 BI T D， ZHENG J N， ZHANG J X， et al. Serum complement C4 is an important prognostic factor for IgA nephropathy： A retrospective study［J］. BMC nephrol， 2019， 20（1）： 244. doi:10.1186/s12882-019-1420-0
23 TORIKOSHI K， ENDO T， TSUKAMOTO T， et al. Serum IgA/C3 ratio： A useful marker of disease activity in patients with IgA nephropathy［J］. Int Urol Nephrol， 2024， 56（10）： 3389-3396. doi:10.1007/s11255-024-04104-7
24 MEDJERAL-THOMAS N R， LOMAX-BROWNE H J， BECKWITH H， et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy［J］. Kidney Int， 2017， 92（4）： 942-952. doi:10.1016/j.kint.2017.03.043
25 GUO W Y， ZHU L， MENG S J， et al. Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy［J］. J Am Soc Nephrol， 2017， 28（11）： 3175-3181. doi:10.1681/asn.2017010076
26 LUO H L， HE C， XUE H， et al. Serum human epididymis protein 4 is associated with disease severity in patients with IgA nephropathy［J］. Clinical Biochem， 2024， 123： 110701. doi:10.1016/j.clinbiochem.2023.110701
27 SHIMIZU C， MATSUMOTO K， FUJITA T， et al. Imbalance of interleukin-18 and interleukin-18 binding protein in patients with IgA nephropathy implicating renal vasculopathy［J］. Clin Lab， 2015， 61（1/2）： 23-30. doi:10.7754/clin.lab.2014.140515
28 XU C， PAN K， LI J， et al. Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy［J］. Immunol Res， 2024， 72（6）： 1350-1364. doi:10.1007/s12026-024-09533-1
29 GROZA Y， JEMELKOVA J， KAFKOVA L R， et al. IL-6 and its role in IgA nephropathy development［J］. Cytokine Growth Factor Rev， 2022， 66： 1-14. doi:10.1016/j.cytogfr.2022.04.001
30 SUN Y， CAI H， GE J， et al. Tubule-derived INHBB promotes interstitial fibroblast activation and renal fibrosis［J］. J Pathol， 2022， 256（1）： 25-37. doi:10.1002/path.5798
31 FUKUDA A， MINAKAWA A， SATO Y， et al. Excretion Patterns of Urinary Sediment and Supernatant Podocyte Biomarkers in Patients with CKD［J］. Kidney360， 2022， 3（1）： 63-73. doi:10.34067/kid.0004772021
32 ASAO R， ASANUMA K， KODAMA F， et al. Relationships between levels of urinary podocalyxin， number of urinary podocytes， and histologic injury in adult patients with IgA nephropathy［J］. Clin J Am Soc Nephrol， 2012， 7（9）： 1385-1393. doi:10.2215/cjn.08110811
33 PETERS H P E， WAANDERS F， MEIJER E， et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy［J］. Nephrol Dial Transplant， 2011， 26（11）： 3581-3588. doi:10.1093/ndt/gfr135
34 ZHAO S， SUN Y， MAO Q， et al. Exosomal miR-4639 and miR-210 in Plasma and Urine as Biomarkers in IgA Nephropathy［J］. Nephron， 2022， 146（6）： 539-552. doi:10.1159/000523924
35 LI S， HAO H， LI R， et al. Urinary Exosomal MicroRNAs as New Noninvasive Biomarkers of IgA Nephropathy［J］. Tohoku J Exp Med， 2022， 256（3）： 215-223. doi:10.1620/tjem.256.215
Options
Outlines

/

〈 〉